TLDR
- BioNTech stock fell around 8% Friday after it ended a Phase 2 trial for mRNA cancer vaccine autogene cevumeran in colorectal cancer
- An independent safety board recommended stopping the trial early, citing futility and an imbalance in survival outcomes between treatment groups
- This is the second trial failure for autogene cevumeran in 2026, following a bladder cancer halt in March
- The setback contrasts sharply with last week’s mRNA rally, when Moderna and Merck reported a successful Phase 3 melanoma vaccine trial
- BioNTech still holds €16.6 billion in cash, and its pancreatic cancer trial remains ongoing
BioNTech stock dropped roughly 8% on Friday after the company and Genentech terminated a Phase 2 clinical trial for their mRNA cancer vaccine in colorectal cancer. The stock was trading around $104 before the announcement.
The trial was evaluating autogene cevumeran as an add-on treatment for patients with high-risk Stage II or Stage III colorectal cancer following surgery.
An independent data safety monitoring board found an imbalance in overall survival between the two treatment arms. The board concluded that continuing would be futile and unlikely to change the outcome.
The trial had actually crossed its futility boundary back in October 2025. At that point, though, the board decided the data was not mature enough to draw firm conclusions on efficacy.
This is the second time autogene cevumeran has hit a wall. In March, BioNTech and Genentech halted a bladder cancer trial for the same vaccine, citing changes in the standard-of-care landscape.
A Tale of Two mRNA Vaccines
The timing here is brutal. Just last week, BioNTech stock surged to its best session in six years after Moderna and Merck reported a successful Phase 3 trial for their mRNA melanoma vaccine combined with Keytruda.
That result sent Moderna shares up roughly 177% and lifted the entire mRNA sector. Friday’s news is a sharp reminder that success in one cancer does not mean success across the board.
The biological reason comes down to tumor type. Melanoma is considered an immunologically “hot” cancer with a high mutation rate that tends to respond well to immune-based treatments. Colorectal cancer is considered “cold” and has historically resisted immunotherapy.
There is also a trial design difference. Moderna combined its vaccine with Keytruda, a proven checkpoint inhibitor. BioNTech tested autogene cevumeran as a standalone monotherapy, which set a much higher clinical bar.
What Comes Next for BioNTech
BioNTech Chief Medical Officer Prof. Özlem Türeci said the results were disappointing but offered scientific insight into why immune-suppressive tumors resist treatment. She added that the findings would help shape future mRNA-based cancer treatments.
Despite the setback, BioNTech’s financial position is solid. The company reported €16.6 billion in cash and securities in Q2 2026, even while posting a net loss of €820.8 million for the quarter.
One trial still stands. BioNTech’s Phase 2 pancreatic cancer study evaluates autogene cevumeran in combination with checkpoint inhibition and chemotherapy, and it continues as planned.
Investors are now looking toward the ESMO Congress in October 2026, where data from both BioNTech and Moderna could be presented side by side.
BioNTech also has an interim analysis of its BNT113 trial in head and neck cancer on the horizon. Head and neck cancer is immunotherapy-sensitive, making it a potentially stronger setting for the vaccine.
Roche, the parent company of Genentech, saw its U.S.-listed stock fall around 1.2% on Friday following the announcement.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
